<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903093</url>
  </required_header>
  <id_info>
    <org_study_id>B7451061</org_study_id>
    <nct_id>NCT04903093</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, CROSSOVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF ABROCITINIB ORAL SUSPENSION AND EFFECT OF AN ACID-REDUCING AGENT ON THE BIOAVAILABILITY OF ABROCITINIB COMMERCIAL TABLET AND TO ASSESS THE TASTE OF ABROCITINIB ORAL FORMULATIONS IN HEALTHY ADULT PARTICIPANTS AGED 18 TO 55 YEARS OF AGE.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of 2 parts: Part A is to estimate the relative bioavailability of a&#xD;
      single 200 mg dose of abrocitinib oral suspension (Test formulation) compared to the&#xD;
      commercial abrocitinib tablet (200 mg) (Reference formulation). The effect of an&#xD;
      acid-reducing agent on the pharmacokinetics of abrocitinib and its metabolites will also be&#xD;
      evaluated by administering abrocitinib 200 mg commercial tablet with or without famotidine 40&#xD;
      mg, as an acid-reducing agent. Part B is to assess the taste and palatability of six&#xD;
      different abrocitinib oral suspension formulations. Additionally, the safety and tolerability&#xD;
      of abrocitinib tablet (in Part A) and abrocitinib oral suspension formulations (in Part B)&#xD;
      will be assessed when given with or without famotidine 40 mg once daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 randomized study in healthy participants to estimate the relative&#xD;
      bioavailability of abrocitinib oral suspension (Test formulation) compared to commercial&#xD;
      abrocitinib tablet (Reference formulation) under fasted condition. The effect of an&#xD;
      acid-reducing agent on the pharmacokinetics of the commercial tablet formulation will be&#xD;
      evaluated by administering abrocitinib 200 mg commercial tablet with famotidine 40 mg, as an&#xD;
      acid-reducing agent. Assessment of taste and palatability of six different abrocitinib&#xD;
      suspension formulations will also be performed. This study consists of 2 parts, as listed&#xD;
      below:&#xD;
&#xD;
      Part A&#xD;
&#xD;
      Part A of the study will be an open label, randomized, single dose, crossover, 3-treatment, 6&#xD;
      sequence, 3-period design in healthy male and/or female adult participants (18-55 years).&#xD;
      Healthy participants will be screened within 28 days prior to the first administration of the&#xD;
      study intervention to confirm that they meet the participant selection criteria for the&#xD;
      study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in&#xD;
      the CRU until discharge, on Day 2 of Period 9 in Part B, after completing both Parts A and B&#xD;
      of the study. In Part A, participants will be randomized to receive one of the following: a&#xD;
      single 200 mg dose of abrocitinib commercial tablet (Treatment A), a single 200 mg dose of&#xD;
      abrocitinib oral suspension formulation 1 (Treatment B), or famotidine (40 mg) administered&#xD;
      120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C). All&#xD;
      participants will be fasting for at least 10 hours before taking abrocitinib.&#xD;
&#xD;
      Part B&#xD;
&#xD;
      Part B will be a single-blind, randomized, 6-period, crossover study in healthy male and/or&#xD;
      female adult participants (18-55 years). For any new healthy participants joining Part B&#xD;
      only, screening will be performed within 28 days prior to the first administration of the&#xD;
      study intervention to confirm that they meet the participant selection criteria for the&#xD;
      study. New participants enrolled in Part B only will be admitted to the CRU on Day -1 and&#xD;
      will be confined in the CRU until discharge, which is Day 2 of Period 9. On Day 1 of each&#xD;
      treatment period under fasted conditions, participants will receive a famotidine tablet (40&#xD;
      mg with 240 mL of room temperature water) administered 120 minutes before a single 200 mg&#xD;
      dose of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg&#xD;
      dose of abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least 10&#xD;
      hours before abrocitinib administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Actual">October 26, 2021</completion_date>
  <primary_completion_date type="Actual">October 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part A: open label / Part B: single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 1x200 mg of abrocitinib tablet (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 1x200 mg of abrocitinib tablet (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 1×200 mg of abrocitinib tablet with famotidine 40 mg in Part A (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 1×200 mg of abrocitinib tablet with famotidine 40 mg in Part A (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 200 mg of abrocitinib oral suspension F1 (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of Abrocitinib following the administration of 200 mg of abrocitinib oral suspension F1 (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting overall liking after administering each abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting mouth feel after administering each abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting bitterness after administering each abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting tongue/mouth after administering each abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting salty taste after administering each abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Salty taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting sour taste after administering abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulations (F1-F6)</time_frame>
    <description>Sour taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects reporting sweet taste after administering abrocitinib oral suspension formulation (F1-F6) in Part B</measure>
    <time_frame>1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)</time_frame>
    <description>Sweet taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites (M1, M2 and M4) following the administration of 1×200 mg of abrocitinib tablet with or without famotidine 40 mg in Part A (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites (M1, M2 and M4) following the administration of 1×200 mg of abrocitinib tablet with or without famotidine 40 mg in Part A (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse event in Part A and Part B of the study</measure>
    <time_frame>Baseline until Period 9 study day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Abrocitinib Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Abrocitinib Suspension F1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Abrocitinib Tablet + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F1 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F2 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F3 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F4 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F5 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Abrocitinib Suspension F6 + Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib tablet</intervention_name>
    <description>Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part A: Abrocitinib Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F1</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part A: Abrocitinib Suspension F1</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F1</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F1 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F2</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part B: Abrocitinib Suspension F2</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F2 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F3</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part B: Abrocitinib Suspension F3</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F3 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F4</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part B: Abrocitinib Suspension F4</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F4 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F5</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part B: Abrocitinib Suspension F5</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F5 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib Suspension F6</intervention_name>
    <description>Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Part B: Abrocitinib Suspension F6</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F6 + Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.</description>
    <arm_group_label>Part A: Abrocitinib Tablet + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F1 + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F2 + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F3 + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F4 + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F5 + Famotidine</arm_group_label>
    <arm_group_label>Part B: Abrocitinib Suspension F6 + Famotidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including a detailed medical history, complete physical examination,&#xD;
             laboratory tests, and cardiovascular tests.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus&#xD;
             infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis&#xD;
             B core antibody (HepBcAb), or hepatitis C virus antibody (HCVAb).&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year).&#xD;
&#xD;
        Evidence or history of clinically significant dermatological condition (eg, atopic&#xD;
        dermatitis or psoriasis) or visible rash present during physical examination.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half lives (whichever is longer) prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  A positive urine drug test.&#xD;
&#xD;
          -  Selected laboratory abnormalities.&#xD;
&#xD;
          -  History of alcohol abuse or binge drinking and/or any other illicit drug use or&#xD;
             dependence within 6 months of Screening.&#xD;
&#xD;
          -  History of tuberculosis (TB) (active or latent).&#xD;
&#xD;
          -  Any history of chronic infections, any history of recurrent infections, any history of&#xD;
             latent infections, or any acute infection within 2 weeks of baseline.&#xD;
&#xD;
          -  Pregnant female participants; breastfeeding female participants; female participants&#xD;
             of childbearing potential who are unwilling or unable to use an acceptable method of&#xD;
             contraception.&#xD;
&#xD;
          -  History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent&#xD;
             localized dermatomal herpes zoster.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7451061</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abrocitinib</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Relative Bioavailability</keyword>
  <keyword>Taste Assessment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>Abrocitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

